Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0AW8E
|
|||
| Former ID |
DNCL001853
|
|||
| Drug Name |
Tezosentan
|
|||
| Synonyms |
Tezosentan; 180384-57-0; N-(2-(2-(2H-Tetrazol-5-yl)pyridin-4-yl)-6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)pyrimidin-4-yl)-5-isopropylpyridine-2-sulfonamide; UNII-64J9J55263; CHEMBL61780; 64J9J55263; N-(6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-(1H-tetrazol-5-yl)-4-pyridinyl)-4-pyrimidinyl)-5-(1-methylethyl)-2-pyridinesulfonamide; 2-Pyridinesulfonamide, N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-(1H-tetrazol-5-yl)-4-pyridinyl)-4-pyrimidinyl)-5-(1-methylethyl)-; Tezosentan [INN]
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cardiac disease [ICD-11: BA00-BE2Z; ICD-10: I50] | Phase 3 | [1] | |
| Company |
Actelion Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H27N9O6S
|
|||
| Canonical SMILES |
CC(C)C1=CN=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC(=NC=C3)C4=NNN=N4)OCCO)OC5=CC=CC=C5OC
|
|||
| InChI |
1S/C27H27N9O6S/c1-16(2)18-8-9-22(29-15-18)43(38,39)34-26-23(42-21-7-5-4-6-20(21)40-3)27(41-13-12-37)31-24(30-26)17-10-11-28-19(14-17)25-32-35-36-33-25/h4-11,14-16,37H,12-13H2,1-3H3,(H,30,31,34)(H,32,33,35,36)
|
|||
| InChIKey |
TUYWTLTWNJOZNY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 180384-57-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00458276) Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.